Cytokinetics GAAP EPS of -$1.50 misses by $0.05, revenue of $17.75M beats by $9.73M
Source: SeekingAlpha
2026-02-24 16:02:25 ET
More on Cytokinetics
- Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Cytokinetics: Small Label Differences With Big Commercial Stakes
- Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript
- Cytokinetics Q4 2025 Earnings Preview
- Cytokinetics gains FDA approval of aficamten for hypertrophic cardiomyopathy
Read the full article on Seeking Alpha
For further details see:
Cytokinetics GAAP EPS of -$1.50 misses by $0.05, revenue of $17.75M beats by $9.73M
Cytokinetics Incorporated
NASDAQ: CYTK
CYTK Trading
3.56% G/L:
$63.905 Last:
620,280 Volume:
$62.24 Open:
CYTK Latest News
March 09, 2026 02:38:32 pm
Cytokinetics Insider Exercises Options Worth Over $920,000 as Heart Drug Hits the Market
CYTK Stock Data
$7,892,201,167
118,963,776
0.07%
158
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
